What it is
PT-141, also called bremelanotide, is a man-made chain of amino acids (a peptide) for sexual dysfunction. It works through the melanocortin system, a signalling network in the brain that regulates sexual arousal — so it acts on desire itself rather than on blood flow the way Viagra does.
This is the nasal spray form. It comes ready-mixed in an atomizer — a small pump bottle that turns the liquid into a fine mist — delivering 100 micrograms per spray.
It is used for hypoactive sexual desire disorder (HSDD): persistently low sexual desire that is not explained by another medical or psychiatric condition, by relationship problems, or by the side effects of a medication.
Because the spray goes in through the nose rather than the stomach, you do not need to be fasted.
This entry covers dosing and technique for the nasal form. For what PT-141 does, its benefits, and its side effects, see the injectable PT-141 page — the compound is identical.
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide analogue of alpha-MSH, an agonist at central melanocortin receptors — principally MC4R — regulating sexual arousal centrally rather than through cavernosal haemodynamics.
This is the intranasal presentation: a pre-mixed atomizer dispensing 100 mcg per actuation, twice the per-actuation dose of the intranasal oxytocin sold alongside it.
Stated indication: hypoactive sexual desire disorder, or any condition producing persistent low sexual desire not attributable to an existing medical or psychiatric condition, relationship problems, or medication side effects.
The route bypasses the gastrointestinal tract, so fasting is irrelevant.
This entry is a dosing and technique sheet. For benefits, side effects, and contraindications, see the injectable PT-141 entry, which covers the same molecule.
What it does
This entry focuses on dosing and technique for the nasal form. The compound is the same as the injectable, so see that page for the full detail on desire, arousal, orgasm, and confidence.
What this page specifies is the target: hypoactive sexual desire disorder, or any other condition causing persistently low sexual desire that is not down to an existing medical or psychiatric condition, relationship problems, or medication side effects.
There is no cycle. You take it 30 to 60 minutes before sexual activity, and the effect comes on in that window.
This entry documents indication, timing, technique, and dispense rate only. The molecule is identical to the injectable — see that entry for the effect profile across libido, orgasmic response, genital sensitivity, erectile quality, and sexual anxiety.
Stated indication: HSDD or any condition producing persistent low sexual desire not attributable to an existing medical or psychiatric condition, relationship problems, or medication side effects.
No cycle applies — dosing is episodic, 30-60 minutes pre-activity, matching the stated onset window.
Benefits
Evidence grades: what the labels mean
- Human trials Supported by randomised or placebo-controlled human trials.
- Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
- Animal or lab only Shown in animal or cell studies only; not yet tested in people.
- Anecdotal No published studies; based on user reports or theory.
Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.
- For the full list of benefits, see the injectable PT-141 page — the compound is identical.Human trials
- What it does specify: it addresses hypoactive sexual desire disorder and other causes of persistently low sexual desire.Human trials
- What the nasal route adds: no injection, and no need to be fasted, because it bypasses the stomach entirely.Anecdotal
- Research trials have consistently used doses in the 10 to 20 milligram range without adverse effects, which is why no maximum dose is set for the spray.Limited human data
- For the benefits profile, see the injectable PT-141 entry.Human trials
- Stated indication: HSDD and other causes of persistent low sexual desire.Human trials
- Route-specific: needle-free; bypasses the GI tract, so fasting is irrelevant.Anecdotal
- No per-dose maximum is set for the spray: research trials consistently used 10-20 mg without adverse effects, and even the entire atomizer's contents are considered safe provided the dose was increased gradually over time.Anecdotal
Reconstitution and dosing
The nasal spray comes ready to use in an atomizer that delivers 100 micrograms per spray. There is no mixing to do. Keep the atomizer in the fridge.
There is no cycle. You take it 30 to 60 minutes before sexual activity, which is also how long it takes to come on. Any time of day is fine, and you do not need to be fasted.
Start with 3 to 4 sprays — 300 to 400 micrograms — 30 to 60 minutes before sexual activity.
Over time you can increase the dose gradually as needed to get results. Each step up should be held until you tolerate it before going up again.
No maximum dose is set for the spray. The reasoning is that research trials have consistently used doses in the 10 to 20 milligram range without adverse effects, so even the whole atomizer would be safe as long as you built up to it gradually. That is a much higher ceiling than the injectable PT-141 entry allows, and the two forms differ on this point — the injectable entry caps the dose at 2.5 milligrams and says never to exceed it. If you are moving between the two forms, the more cautious figure is the safer one to work from.
The frequency limits are firm and identical to the injectable. Never more than one dose in 24 hours. Never more than 8 doses in a month.
Technique matters. Always split the dose between both nostrils as much as you can. This exposes more of the nasal lining to the spray, reduces how much runs down your throat and gets swallowed, and gives more consistent absorption — because congestion, mucus, airflow, and the normal alternating cycle between nostrils mean one nostril may absorb less well than the other at any given moment.
Do not tilt your head back. Tip your head forward, angle the atomizer toward the outside of your nose, roughly toward the outer corner of your eye, then sniff gently as you spray.
Pre-mixed atomizer at 100 mcg per actuation; no reconstitution. Refrigerate.
No cycle — episodic dosing, 30-60 minutes pre-activity, matching the stated onset window. Any time of day; fasting irrelevant.
Initial dose 3-4 sprays (300-400 mcg), 30-60 minutes pre-activity, titrated upward over time as needed for effect, holding each increment until tolerated before escalating further.
Ceilings: 1 dose per 24 hours, 8 doses per month. These are the same figures the injectable page gives, and they are desensitisation controls rather than acute toxicity limits — so they apply to total melanocortin exposure across both routes, not per route.
Two points worth flagging. First, no maximum dose is set for the intranasal form, on the reasoning that research trials consistently used 10-20 mg without adverse effects and that even the entire atomizer's contents would be safe given gradual escalation. The injectable entry, by contrast, caps at 2.5 mg and says never to exceed it under any circumstances. Those positions are irreconcilable; the conservative figure is the defensible one. Second, no fixed escalation step size has been established (2-4 sprays is the likely increment), so treat it as an increment-and-hold instruction without a specified step size.
Technique is not incidental to dose. Split every dose between both nostrils: this increases mucosal surface area exposed, decreases posterior runoff and swallowed loss, and evens out absorption against congestion, mucus, airflow, and the normal nasal cycle, any of which can render one nostril substantially less effective at a given moment. Head forward, never back; angle the atomizer laterally toward the outer canthus; sniff gently rather than sharply.
Nasal atomizer — 100 mcg per spray
Cycle: No cycle — dosed on demand. Never more than 1 dose in 24 hours, and never more than 8 doses in a month · Frequency: 30–60 minutes before sexual activity; any time of day; fasting not required
| When | Dose | How often |
|---|---|---|
| Initial dose | 3–4 sprays (300–400 mcg) | once, 30–60 minutes before sexual activity |
| Escalation — increase gradually as needed, holding each step until tolerated | Add sprays incrementally above 3–4 (300–400 mcg) | max 1 dose in 24 hours |
| Maximum — no cap is set for the nasal form, given trials at 10–20 mg without adverse effects; the injectable entry caps at 2.5 mg, so treat that as the cautious ceiling | No stated cap; 2.5 mg (25 sprays) is the injectable page's limit | max 8 doses per month |
Who should avoid it
- No contraindications are documented for the nasal form or the injectable PT-141 form. That is an absence of information, not a statement that it is safe for everyone.
- The limits that are given are about frequency. Never take more than one dose in 24 hours.
- Never take more than 8 doses in a month.
- The injectable page explains why: long-term use may desensitise the melanocortin system so it works less well, and it states that exceeding the monthly maximums could damage your health.
- The monthly limit covers PT-141 in total, not each form separately — if you use both the spray and the injection, count them together.
- One symptom warning from the injectable page: if dizziness and blurred vision happen at the same time, see a doctor immediately.
- No contraindication list exists for either the intranasal or the injectable form. Treat this as missing information rather than a safety claim.
- Hard ceiling: 1 dose per 24 hours.
- Hard ceiling: 8 doses per month.
- Rationale from the injectable page: long-term use desensitises the melanocortin system, reducing effectiveness; exceeding monthly maximums could damage health.
- The cap is a property of the receptor system, not of a route — count doses across intranasal and subcutaneous together.
- Red flag from the injectable page: concurrent dizziness and blurred vision warrants immediate physician consultation.
Side effects
- Side effects match the injectable PT-141 form. The common ones are flushing — one of the two most common, reported in roughly 20 to 40% of users.
- Headaches — the other most common, at the same rate.
- Nausea, in about 15% of users.
- Irritation. These are generally mild.
- Less common but more serious: vomiting.
- Less common but more serious: blurred vision.
- Less common but more serious: dizziness.
- Less common but more serious: joint pain or swelling.
- Less common but more serious: a runny or blocked nose — worth noting on the nasal route in particular.
- Less common but more serious: fatigue.
- If dizziness and blurred vision occur together, see a doctor immediately.
- Nasal sprays in general can cause local irritation or drip into the throat. Splitting each dose between both nostrils and not tilting your head back reduces both.
- Side-effect profile as for the injectable form: flushing — approximately 20-40% of users, generally mild.
- Headache — same incidence band.
- Nausea — approximately 15%.
- Irritation.
- Less common but more serious: vomiting.
- Less common but more serious: blurred vision.
- Less common but more serious: dizziness.
- Less common but more serious: joint pain or swelling.
- Less common but more serious: rhinorrhoea or nasal congestion — of particular note on this route, where it also degrades absorption.
- Less common but more serious: fatigue.
- Concurrent dizziness and blurred vision warrants immediate physician consultation.
- Route-specific: local mucosal irritation and posterior drip, both mitigated by splitting the dose between nostrils and by the head-forward technique.
User reports
User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.
Stacking
The same peptide in injected form, on the same 45 to 60 minute timing. Use one or the other — the limit of 8 doses a month covers both together, not 8 of each. Note also that the injectable page sets a firm maximum dose where the nasal page does not.
Same molecule, comparable pre-dose window. The 8-doses-per-month cap belongs to the melanocortin system, not to a route, so count across both. Note the two forms differ on a per-dose ceiling: the injectable caps at 2.5 mg, the intranasal sets no cap at all.
Also a nasal spray on similar timing. PT-141 drives desire while Oxytocin drives bonding and emotional connection — Oxytocin is a common PT-141 partner for exactly that reason.
A common PT-141 partner for connection, bonding, and emotional intimacy. Matching routes matches the onset windows, which makes co-timing straightforward, and the receptor systems are genuinely independent.
The HCG page suggests PT-141 as a partner for libido and sexual function alongside its hormonal effect.
A common HCG partner for libido and sexual function. HCG corrects the endocrine substrate while PT-141 acts centrally on desire — complementary rather than overlapping.
The Kisspeptin page names Kisspeptin + PT-141 + HCG as a combination for sex drive, hormone balance, and fertility together.
Kisspeptin + PT-141 + HCG is a common libido and fertility stack — HPG-axis restoration plus central melanocortin arousal.
Dosing figures have been reviewed and units are recomputed from the stated protocol.